Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
2021; Massachusetts Medical Society; Volume: 384; Issue: 18 Linguagem: Inglês
10.1056/nejmoa2033400
ISSN1533-4406
AutoresSusan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova, Patrick Phillips, Kia Bryant, Kelly E. Dooley, Melissa Engle, Stefan Goldberg, Ha Phan, James Hakim, John L. Johnson, Madeleine Lourens, Neil Martinson, Grace Muzanyi, Kim Narunsky, Sandy Nerette, Nhung Viet Nguyen, Thuong Pham, Samuel Pierre, Anne Purfield, Wadzanai Samaneka, Radojka M. Savić, Ian Sanne, Nigel Scott, Justin Shenje, Erin Sizemore, Andrew Vernon, Ziyaad Waja, Marc Weiner, Susan Swindells, Richard E. Chaisson,
Tópico(s)Mycobacterium research and diagnosis
ResumoRifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.
Referência(s)